SPRY
Ars Pharmaceuticals Inc
2 super-investors hold SPRY worth a combined $22M. The largest position: Daniel Loeb at 0.4% of their portfolio. This quarter the cohort logged 1 buy and 0 sells on the name. Cohort Conviction Score: 25 — ranked #545 of 724 scored stocks.
Why super-investors own SPRY
Daniel Loeb is the higher-conviction holder here, with SPRY representing 0.4% of his portfolio at $8M — a position he added to in 2026Q1. Joel Greenblatt also holds $14M in the stock, though it registers as a rounding-error 0.0% of his portfolio, suggesting a more incidental allocation. Cohort interest remains thin at just two holders, and the ownership history is erratic — the stock cycled in and out of the group's filings before settling at one, then two owners over the past two quarters. No exits or new entrants emerged this quarter, making Loeb's add the sole signal of incremental conviction within a still-narrow ownership base.
AI-synthesized from 13F filings. Not investment advice.
Cohort owners over time
2024Q3 → 2026Q1How many of the cohort members held this stock each quarter.
Owners (2) · click any column to sort
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Joel Greenblatt | <0.1% | 21q | $14M | 1,773,188 |
| 2 | Daniel Loeb | 0.4% | 2q | $8M | 1,000,000 |
Owners of SPRY also hold
Recent activity (1)
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Daniel Loeb | ADD | 0.4% | +80% | $8M | May 15, 2026 |
Long US equity 13F-HR filings only. CUSIP 82835W108. Not investment advice.